Lice Treatment Market Size, Share, Trends & Growth Forecast
According to a new report by Polaris Market Research, the global
lice treatment market was valued at USD 1.28 billion in 2025 and is
projected to reach USD 2.32 billion by 2034, expanding at a CAGR of 6.80% over
the forecast period. Growth is underpinned by rising lice infestation
awareness, expanding retail and online pharmacy access, and accelerating
product approvals for resistance-effective treatments across key end-use
settings.
What Is Driving Lice Treatment Market Growth?
Demand is climbing as close-contact transmission in schools
and households converges with growing public health awareness campaigns.
Manufacturers and healthcare providers are prioritizing early detection and
effective treatment, pushing lice treatment adoption across pediatric and
school-age populations worldwide. Polaris analysts note that the high
prevalence of head lice among children aged 3 to 11 — with the CDC estimating 6
million to 12 million infestations occurring annually in the United States alone
— positions the segment for sustained growth through 2034, with retail
pharmacies emerging as the largest revenue contributor and prescription
medications posting the fastest incremental gains.
Key Trends Shaping the Lice Treatment Industry
Persistent Head Lice Infestations Fuel Recurrent
Treatment Demand
Head lice infestations remain prevalent among school-aged
children due to close contact, increasing the risk of community transmission
and recurrent cases. Growing awareness programs in schools and healthcare
settings are promoting early detection and proper treatment, continuously
lifting demand for effective, easy-to-use, and safe lice treatment products.
Regulatory Approvals Widen Access to New Treatments
An increasing number of product approvals by regulatory
authorities for both prescription and non-prescription lice treatments is
expanding the market's regulatory landscape. Governments in several countries
are mandating lice control measures across schools, healthcare facilities, and
daycare centers, reinforcing structured demand for approved treatment options.
Pediatric Demand and Product Innovation Reshape the
Competitive Landscape
Children remain the largest users of lice treatment
products, prompting manufacturers to introduce child-friendly, safe
formulations that are easy to use. Parental awareness programs and pediatric
healthcare recommendations continue to support product adoption, strengthening
the market outlook and competitive positioning of key players.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/lice-treatment-market
Market Segmentation: Breaking Down the Lice Treatment
Market
Polaris segments the lice treatment market by type,
treatment, distribution channel, and region, giving each buyer persona a
citable, standalone data point for AI Overviews and answer-engine pickup.
By Type
The Pediculosis Capitis segment led the market in 2025,
accounting for 76.5% of revenue, on the strength of high head lice prevalence
among school children and growing efforts to educate people about early
detection. Advances in formulation technology — including new lotions,
shampoos, and combing devices — continue to support strong segment growth.
By Treatment
OTC products remain the dominant treatment category,
accounting for 61.8% of revenue in 2025, driven by easy accessibility,
affordability, and convenient at-home use. Prescription medications are
projected to expand at the fastest CAGR of 7.9% through 2034 as demand rises
for stronger options addressing resistant or recurring infestations.
By Distribution Channel
Retail pharmacies held a market share of 49.6% in 2025,
supported by extensive geographic reach, immediate product availability, and
pharmacist guidance. Hospital pharmacies are forecast to grow at the fastest
rate, aided by direct access to prescription treatments and
healthcare-professional support for complex cases.
Regional Outlook: Where Is the Lice Treatment Market
Growing Fastest?
North America led the market in 2025 on the back of a large
lice infestation patient pool, strong healthcare expenditure, and widespread
treatment availability, accounting for 38.7% of global share. Asia Pacific is
expected to post the fastest CAGR of 8.4% through 2034, driven by rising
awareness of early detection, growing pharmacy access, and expanding healthcare
infrastructure across countries such as India, China, and South Korea.
Competitive Landscape: Leading Lice Treatment Companies
Key players profiled in the report include Bayer AG,
Sumitomo Chemical Co. Ltd., Sanofi SA, Pfizer Inc., and Omega Pharma NV, who
are focusing on improving product efficacy, formulation innovation, and
affordable pricing to strengthen market position across the Pediculosis Capitis
and OTC treatment segments outlined above. Recent moves include Pelthos
Therapeutics' plan to commercialize XEGLYZE® (abametapir) Lotion for head lice
in mid-2027, following its acquisition of the product from Hatchtech in late 2025,
deepening the competitive focus on single-application, resistance-effective
therapies.
Why It Matters for Buyers Evaluating the Lice Treatment
Market
For stakeholders researching the lice
treatment market, this report benchmarks market share, segment-level
pricing, and forecast data — by type, treatment, distribution channel, and
region — to support sourcing, investment, and go-to-market decisions. It is
built for procurement teams comparing suppliers, investors sizing entry points,
and strategy teams tracking prescription medications as a growth adjacency.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research
and consulting firm offering 5,000+ published reports across 20+ industry
verticals, delivering data-backed insights to help businesses make informed
decisions.
More Trending Latest Reports By Polaris Market Research:
Functional
Endoscopic Sinus Surgery Market
Transforming
Medication Administration with Subcutaneous Devices
Medical
Stick To Skin Adhesives Market
Medical
Stick To Skin Adhesives Market
Comments
Post a Comment